Malta - enska - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - enska - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Malta - enska - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - enska - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - enska - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Ísrael - enska - Ministry of Health

novartis israel ltd - epirubicin hydrochloride - concentrate for solution for infusion - epirubicin hydrochloride 2 mg/ml - epirubicin - for the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma (high doses), ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. intravesical administration of farmorubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after stransurethral resection. i.v. administration for the treatment of advanced bladder carcinoma.